DE69130996T2 - Gezielte Zerstörung neoplastischer Zellen mit Hilfe von Retrovirusvektor-produzierenden Packungszelllinien - Google Patents

Gezielte Zerstörung neoplastischer Zellen mit Hilfe von Retrovirusvektor-produzierenden Packungszelllinien

Info

Publication number
DE69130996T2
DE69130996T2 DE69130996T DE69130996T DE69130996T2 DE 69130996 T2 DE69130996 T2 DE 69130996T2 DE 69130996 T DE69130996 T DE 69130996T DE 69130996 T DE69130996 T DE 69130996T DE 69130996 T2 DE69130996 T2 DE 69130996T2
Authority
DE
Germany
Prior art keywords
neoplastic cells
help
cell lines
packaging cell
retrovirus vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69130996T
Other languages
English (en)
Other versions
DE69130996D1 (de
Inventor
Robert L Martuza
Xandra O Breakfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27078482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69130996(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by General Hospital Corp filed Critical General Hospital Corp
Application granted granted Critical
Publication of DE69130996D1 publication Critical patent/DE69130996D1/de
Publication of DE69130996T2 publication Critical patent/DE69130996T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69130996T 1990-09-14 1991-09-16 Gezielte Zerstörung neoplastischer Zellen mit Hilfe von Retrovirusvektor-produzierenden Packungszelllinien Expired - Fee Related DE69130996T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58205590A 1990-09-14 1990-09-14
US74665591A 1991-08-16 1991-08-16

Publications (2)

Publication Number Publication Date
DE69130996D1 DE69130996D1 (de) 1999-04-22
DE69130996T2 true DE69130996T2 (de) 1999-07-29

Family

ID=27078482

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69130996T Expired - Fee Related DE69130996T2 (de) 1990-09-14 1991-09-16 Gezielte Zerstörung neoplastischer Zellen mit Hilfe von Retrovirusvektor-produzierenden Packungszelllinien

Country Status (5)

Country Link
EP (1) EP0476953B1 (de)
JP (1) JPH05246895A (de)
AT (1) ATE177648T1 (de)
CA (1) CA2051288C (de)
DE (1) DE69130996T2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6241982B1 (en) 1988-03-21 2001-06-05 Chiron Corporation Method for treating brain cancer with a conditionally lethal gene
US6569679B1 (en) 1988-03-21 2003-05-27 Chiron Corporation Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
US5716826A (en) * 1988-03-21 1998-02-10 Chiron Viagene, Inc. Recombinant retroviruses
US5662896A (en) 1988-03-21 1997-09-02 Chiron Viagene, Inc. Compositions and methods for cancer immunotherapy
US6133029A (en) 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
EP0637966B1 (de) * 1992-05-01 1997-08-27 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Warte-effekt bei tumorzerstörender therapie
GB9305759D0 (en) * 1993-03-19 1993-05-05 Medical Research Council And T Hiv therapy method and agents
WO1995009654A1 (en) * 1993-10-01 1995-04-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Gene therapy of the nervous system
CA2173495A1 (en) * 1993-10-06 1995-04-13 Kenneth W. Culver Treatment of tumors by genetic transformation of tumor cells with genes encoding negative selective markers and cytokines
CA2158936C (en) 1993-11-18 2012-02-21 Jack R. Barber Compositions and methods for utilizing conditionally lethal genes
US6451571B1 (en) 1994-05-02 2002-09-17 University Of Washington Thymidine kinase mutants
EP0758387B1 (de) * 1994-05-02 2001-12-19 University of Washington Thymidin-kinase-mutanten
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
AU4856696A (en) 1995-01-17 1996-08-07 Genetic Therapy, Inc. Delivery of therapeutic agents by gene therapy
CA2222559A1 (en) * 1995-06-27 1997-01-16 Bavarian Nordic Research Institute A/S Encapsulated cells producing viral particles
US6602499B1 (en) 1998-04-30 2003-08-05 The General Hospital Corporation Combination viral-based and gene-based therapy of tumors
US7575924B2 (en) 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
ATE527347T1 (de) 2001-08-02 2011-10-15 Inst Clayton De La Rech Verfahren und zusammensetzungen im zusammenhang mit verbesserten lentivirusvektor- produktionssystemen
IL161229A0 (en) 2001-10-02 2004-09-27 Inst Clayton De La Rech Methods and compositions relating to restricted expression lentiviral vectors and their applications.

Also Published As

Publication number Publication date
EP0476953A3 (en) 1992-12-16
EP0476953B1 (de) 1999-03-17
EP0476953A2 (de) 1992-03-25
CA2051288A1 (en) 1992-03-15
DE69130996D1 (de) 1999-04-22
JPH05246895A (ja) 1993-09-24
CA2051288C (en) 2002-02-05
ATE177648T1 (de) 1999-04-15

Similar Documents

Publication Publication Date Title
DE69130996T2 (de) Gezielte Zerstörung neoplastischer Zellen mit Hilfe von Retrovirusvektor-produzierenden Packungszelllinien
DK464087D0 (da) Haloarylnitril-nedbrydende gen, anvendelsen heraf og celler indeholdende dette
FI890406A0 (fi) Polymera material.
BR8903636A (pt) Processo para producao de material polimerico de propileno com ramificacao de cadeia longa,de elevado peso molecular,e processo para tratamento de material polimerico de propileno irradiado
DK158659C (da) 2,4,6-triiod-isophthalsyrederivater, deres fremstilling og roentgenkontrastmidler indeholdende disse.
NO991742D0 (no) Lentivirale vektorer
DE3788498T2 (de) Vektor-Modulatoren und deren Kalibrierung.
DE3689520T2 (de) Durchsichtiger polyäthylenfilm hoher dichte und dessen herstellung.
DK203980A (da) Syrer og estere af 5-(evt. 2-subst.-4-trifluormethyl-evt.6-subst.-phenoxyl)-2-nitro-,-halogen- eller -cyano-alfa-subst.-phenylcarbonyler, oximer og carboxyoximer samt deres anvendelse i herbicider
TR28980A (tr) Hidrofilik polimer bilesimi ve bunu ihtiva eden ürün.
ES2023417B3 (es) Procedimiento para polimerizar una o mas 1-olefinas en fase gaseosa en presencia de material inorganico pulverulento.
IT8420245A0 (it) Fune di trasporto ad organi raschianti in materia plastica.
BR8804063A (pt) Composicao polimerica,processo e produto
NO884697D0 (no) Brannhemmende polymerblanding.
NL930010I1 (nl) Recombinant DNA-moleculen en de produktie daarvan.
DE3674789D1 (de) Balken und dessen herstellung.
FR2466872B1 (fr) Pile au lithium. bioxyde de manganese et procede de realisation d'une telle pile
DE3676901D1 (de) Wickelachse zum anbringen von umhuellungsmaterial.
TR20254A (tr) 1,3,4-tiyadiyazol-2-karboksilik asit tuerevleri,bu bilesim imaline mahsus usuller ve bunlari ihtiva eden fungisit ve nemasit maddeler
DE3688883D1 (de) Strukturmaterial und dessen herstellung.
NO803812L (no) Med hydrauliske bindemidler og/eller kunststoffer fremstilt produkt.
DE3775912D1 (de) Photostrukturierbare polyimidmischungen, polyimide auf basis von benzhydroltetracarbonsaeure und deren herstellung.
AT370669B (de) Vorrichtung zum ein- oder beidseitigen besaeumen von brettern, balken u. dgl.
NO912099L (no) Ekspresjon av hiv-proteiner i drosophilia-celler.
FI875287A0 (fi) Foerfarande foer att minska eller helt avlaegsna vatteninnehaollet i vaermekaensliga vaetskeformiga material.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: GROSSE, BOCKHORNI, SCHUMACHER, 81476 MUENCHEN

8339 Ceased/non-payment of the annual fee